Publikationen in Zusammenarbeit mit Forschern von Uppsala University Hospital (19)

2024

  1. EUSOMA quality indicators for non-metastatic breast cancer: An update

    European Journal of Cancer, Vol. 198

2023

  1. Axillary surgery after primary systemic therapy

    Breast Cancer Management for Surgeons: An Examination Guide (Springer International Publishing), pp. 253-264

  2. Evolution and refinement of magnetically guided sentinel lymph node detection in breast cancer: meta-analysis

    The British journal of surgery, Vol. 110, Núm. 4, pp. 410-419

  3. Localization Techniques for Non-Palpable Breast Lesions: Current Status, Knowledge Gaps, and Rationale for the MELODY Study (EUBREAST-4/iBRA-NET, NCT 05559411)

    Cancers, Vol. 15, Núm. 4

2022

  1. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study

    European Urology Open Science, Vol. 40, pp. 38-45

  2. Text mining and word embedding for classification of decision making variables in breast cancer surgery

    European Journal of Surgical Oncology, Vol. 48, Núm. 7, pp. 1503-1509

2021

  1. Correction to: Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS (Intensive Care Medicine, (2020), 46, 12, (2200-2211), 10.1007/s00134-020-06192-2)

    Intensive Care Medicine

  2. The Impact of the COVID-19 Pandemic on Surgical Management of Breast Cancer: Global Trends and Future Perspectives

    Oncologist, Vol. 26, Núm. 1, pp. e66-e77

2020

  1. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS

    Intensive Care Medicine, Vol. 46, Núm. 12, pp. 2200-2211

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. Rationale and Study Design for an Individualized Perioperative Open Lung Ventilatory Strategy in Patients on One-Lung Ventilation (iPROVE-OLV)

    Journal of Cardiothoracic and Vascular Anesthesia, Vol. 33, Núm. 9, pp. 2492-2502

  3. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2018

  1. Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO

    Colorectal Disease, Vol. 20, Núm. 3, pp. 219-227

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2014

  1. Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)

    European Journal of Cancer

2013

  1. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

    European Journal of Cancer, Vol. 49, Núm. 18, pp. 3831-3838

2006

  1. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia

    Journal of the National Cancer Institute, Vol. 98, Núm. 4, pp. 273-284

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051

2001

  1. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European group for blood and marrow transplantation (EBMT)

    Bone Marrow Transplantation, Vol. 27, Núm. 5, pp. 511-515